Hemab Therapeutics Holdings, Inc. (COAG) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$26.00M*; Operating income -$26.08M; Depreciation and amortization $75.00K*.
- 2026-03-31: Basis Reported; EBITDA -$23.54M; Operating income (m); Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA -$15.98M*; Operating income -$16.06M; Depreciation and amortization $77.00K*.
- 2025-03-31: Basis Reported; EBITDA -$16.49M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2025-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$26.00M* | -$26.08M | $75.00K* | (m) | (m) | $23.00K* | -$22.64M* | (m) | $20.34M | $5.74M | $97.00K |
|---|
| 2026-03-31 | Reported | -$23.54M | (m) | (m) | (m) | (m) | $112.00K | -$21.58M | (m) | $19.46M | $4.15M | $12.00K |
|---|
| 2025-06-30 | Reported | -$15.98M* | -$16.06M | $77.00K* | (m) | (m) | $0.00* | -$15.33M* | (m) | $12.87M | $3.18M | $4.00K |
|---|
| 2025-03-31 | Reported | -$16.49M | (m) | (m) | (m) | (m) | $16.00K | -$13.03M | (m) | $14.10M | $2.46M | -$190.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|